Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Stock Market Starts the Day in Positive Territory, Sensex Surges by Over 100 Points, Nifty Crosses 22,650 Mark

Reading Time: < 1 minute

Granules Pharma, a subsidiary of Granules India, has received approval from the US Food & Drug Administration (USFDA) for its generic gout medication, Colchicine Capsules (0.6 mg). This medication is used to prevent or treat gout attacks and is considered therapeutically equivalent to Mitigare Capsules (0.6 mg) by Hikma International Pharmaceuticals LLC. The approval marks a significant milestone for Granules Pharma and opens up new opportunities in the US market.

In contrast, Tata Chemicals experienced a 4.50% decline in its shares following the announcement of a net loss of Rs 818 crore for the fourth quarter ending March 31, 2024. The stock fell on both the BSE and NSE, attributed to reduced income and provisions for exceptional items in the UK business. This news has impacted investors and raised concerns about the company’s financial performance.

On a broader scale, a recent study revealed that 70% of companies prioritize Gen AI to enhance employee efficiency. This highlights the growing importance of artificial intelligence in the workplace and its potential to revolutionize productivity and operations. Additionally, US tile manufacturers have advocated for import tariffs on Indian products, citing unfair competition from subsidized imports supported by the Indian government.

In the financial sector, the rupee declined by 3 paise in early trade, reaching 83.48 against the US dollar. This decline was influenced by the strength of the American currency and rising crude oil prices. However, positive sentiment in domestic equity markets and foreign capital inflows have helped mitigate the rupee’s decline.

Overall, these developments in the business and financial sectors reflect the dynamic nature of the global economy and the challenges and opportunities faced by companies in today’s competitive market. Stay tuned for more updates on the latest business news and market trends.

Taylor Swifts New Album Release Health issues from using ACs Boston Marathon 2024 15 Practical Ways To Save Money